Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 28 Jun 2011 |
| Zealand Pharma's 2010 IPO voted Transaction of the Year at the 2011 European Mediscience Awards | 24 Jun 2011 |
| Positive results for Lyxumia® (lixisenatide) presented at the American Diabetes Association's 71st Annual Scientific Sessions | 24 Jun 2011 |
| Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity | 16 Jun 2011 |
| Additional positive Phase III results with Lyxumia® (lixisenatide) for the treatment of Type 2 diabetes | 31 May 2011 |
| Zealand Pharma to present at UBS Global Specialty Pharmaceuticals Conference 2011 | 23 May 2011 |